Ig Vena

Human Normal Immunoglobulin, the active ingredient in Ig Vena, is an immunoglobulin presented as a solution for injection for intravenous use. It replaces deficient IgG antibodies in patients with primary or secondary immunodeficiency diseases and is employed in certain immune‑mediated conditions. The product provides passive immunity by delivering pooled IgG antibodies that neutralize pathogens and modulate immune responses, helping to reduce infection frequency and severity.

GNH USA supplies Ig Vena as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Ig Vena is used to replace IgG antibodies in disorders affecting humoral immunity. - Primary immunodeficiency diseases: restores IgG levels to reduce the frequency and severity of infections. - Secondary immunodeficiency (e.g., chemotherapy, HIV): supplies exogenous IgG to support immune function during disease‑ or treatment‑induced antibody loss. - Immune thrombocytopenic purpura (off‑label): may modulate auto‑immune activity and help increase platelet counts. - Kawasaki disease (off‑label): used to attenuate inflammation and lower the risk of coronary artery complications.

Ig Vena may be associated with a range of infusion‑related and immunologic reactions.

Common Side Effects: - Headache: mild to moderate pain often occurring during or shortly after infusion. - Fever and chills: transient rise in body temperature and shaking sensations. - Nausea or vomiting: gastrointestinal discomfort following administration. - Fatigue: temporary feeling of tiredness or weakness.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction that can include airway obstruction and hypotension. - Thromboembolic events: clot formation that may lead to vascular occlusion. - Renal dysfunction: acute kidney injury manifested by reduced urine output or elevated creatinine.

Before initiating Ig Vena therapy, several safety considerations should be observed. - Baseline IgG assessment: measure serum immunoglobulin levels to determine replacement need. - Infusion monitoring: observe patients for signs of reactions during the first administration. - Cardiovascular status: adjust infusion rate in patients with heart failure or hypertension. - IgA deficiency with anti‑IgA antibodies: avoid use due to risk of severe anaphylaxis. - Renal function: use caution and monitor renal parameters in patients with existing kidney disease. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Ig Vena can interact with other agents that affect immune function or hemostasis.

Major Interactions (Avoid): - Live vaccines: concurrent administration may result in inadequate vaccine response or infection. - Additional immunoglobulin products: co‑administration can increase risk of hyperviscosity and overload.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin, heparin): monitor for altered coagulation parameters and bleeding risk. - ACE inhibitors: watch for additive hypotensive effects during infusion. - Diuretics: assess fluid balance to prevent volume depletion. - Non‑live vaccines: evaluate immune response as passive antibodies may blunt efficacy.